Who are Placebo followed by zicotinide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-followed-by-zicotinide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo followed by zicotinide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo followed by zicotinide (Placebo followed by zicotinide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: N-type calcium channel blocker. Area: Pain Management.

phase 3 N-type calcium channel blocker N-type voltage-gated calcium channel Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Placebo followed by zicotinide (Placebo followed by zicotinide) — Hospices Civils de Lyon. Ziconotide is a selective N-type calcium channel blocker that reduces neuronal excitability and neurotransmitter release in the spinal cord to alleviate chronic pain.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo followed by zicotinide TARGET	Placebo followed by zicotinide	Hospices Civils de Lyon	phase 3	N-type calcium channel blocker	N-type voltage-gated calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (N-type calcium channel blocker class)

Hospices Civils de Lyon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo followed by zicotinide — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-followed-by-zicotinide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab